We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1B
AUM Growth
+$73.5M
Cap. Flow
-$38M
Cap. Flow %
-3.79%
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$17.5M
2
MDT icon
Medtronic
MDT
+$16.5M
3
TMO icon
Thermo Fisher Scientific
TMO
+$16M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$11.2M
5
RPRX icon
Royalty Pharma
RPRX
+$7.69M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.6M
2
LLY icon
Eli Lilly
LLY
+$12.8M
3
CVS icon
CVS Health
CVS
+$11.6M
4
ELV icon
Elevance Health
ELV
+$11.6M
5
MCK icon
McKesson
MCK
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$73.6B
$14.1M 1.41%
47,000
-33,000
-41% -$9.64M
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
$13.7M 1.37%
220,000
-10,000
-4% -$559K
DXCM icon
28
DexCom
DXCM
$33.1B
$13.6M 1.36%
110,000
+65,000
+144% +$6.64M
PRCT icon
29
Procept Biorobotics
PRCT
$1.24B
$13M 1.3%
310,000
-183,000
-37% -$6.23M
CYTK icon
30
Cytokinetics
CYTK
$10.5B
$12.5M 1.25%
149,912
-50,088
-25% -$1.81M
EXAS
31
DELISTED
Exact Sciences
EXAS
$12.2M 1.22%
165,000
+5,000
+3% +$328K
RPRX icon
32
Royalty Pharma
RPRX
$25.8B
$12.1M 1.21%
429,697
+279,697
+186% +$7.69M
DVAX
33
DELISTED
Dynavax Technologies
DVAX
$11.2M 1.12%
800,000
+100,000
+14% +$1.39M
OSCR icon
34
Oscar Health
OSCR
$8.54B
$10.9M 1.09%
1,192,054
+422,054
+55% +$2.91M
CVS icon
35
CVS Health
CVS
$122B
$10.9M 1.08%
137,500
-162,500
-54% -$11.6M
PRVA icon
36
Privia Health
PRVA
$2.86B
$10.6M 1.06%
460,000
– –
IQV icon
37
IQVIA
IQV
$39.8B
$10.4M 1.04%
45,000
-2,000
-4% -$411K
CNC icon
38
Centene
CNC
$32.9B
$10M 1%
135,000
+105,000
+350% +$7.57M
GKOS icon
39
Glaukos
GKOS
$10.7B
$9.54M 0.95%
120,000
+47,000
+64% +$3.2M
ALKS icon
40
Alkermes
ALKS
$8.29B
$9.43M 0.94%
340,000
-30,000
-8% -$779K
IOVA icon
41
Iovance Biotherapeutics
IOVA
$2.9B
$9.08M 0.91%
1,116,818
+166,818
+18% +$873K
CRL icon
42
Charles River Laboratories
CRL
$13.2B
$8.98M 0.9%
38,000
-6,000
-14% -$1.18M
NUVL
43
DELISTED
Nuvalent
NUVL
$8.31M 0.83%
112,929
+26,918
+31% +$1.67M
ALHC icon
44
Alignment Healthcare
ALHC
$2.86B
$8.18M 0.82%
950,000
-250,000
-21% -$1.83M
NBIX icon
45
Neurocrine Biosciences
NBIX
$16.8B
$8.17M 0.82%
62,000
+7,434
+14% +$856K
EVH icon
46
Evolent Health
EVH
$444M
$7.6M 0.76%
230,000
+85,000
+59% +$2.41M
ALGN icon
47
Align Technology
ALGN
$12.5B
$7.4M 0.74%
+27,000
New +$6.4M
ALNY icon
48
Alnylam Pharmaceuticals
ALNY
$29B
$7.18M 0.72%
37,500
-7,500
-17% -$1.28M
ZBH icon
49
Zimmer Biomet
ZBH
$18.7B
$6.69M 0.67%
55,000
-5,000
-8% -$558K
AVTR icon
50
Avantor
AVTR
$9.29B
$6.67M 0.67%
+292,000
New +$5.98M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rhenman & Partners Asset Management held 100 positions worth $1B, up 7.9% from $928M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $38M in Q4 2023, closing 15 positions and reducing 32 holdings. Its most notable exit was Becton Dickinson, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pfizer worth $16.7M.

  • Rhenman & Partners Asset Management's largest Q4 2023 buy was Pfizer: 580,000 shares worth $16.7M.
  • Rhenman & Partners Asset Management added most to Medtronic in Q4 2023, an estimated $16.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2023 reduction was Eli Lilly, cutting an estimated $12.8M.
  • Rhenman & Partners Asset Management fully exited Becton Dickinson in Q4 2023, selling an estimated $24.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1B portfolio in Q4 2023.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 15 in Q4 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 7.9% quarter-over-quarter to $1B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.